VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study - Trial NCT06409221
Access comprehensive clinical trial information for NCT06409221 through Pure Global AI's free database. This phase not specified trial is sponsored by Concr and is currently Enrolling by invitation. The study focuses on Cancer, Breast,Triple Negative Breast Cancer,Early-stage Breast Cancer. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Non-interventional study, Observational only
Observational
other
Sponsor & Location
Concr
Timeline & Enrollment
N/A
May 01, 2024
Dec 31, 2025
Primary Outcome
Validate accuracy of the Breast cancer therapeutic response predictive algorithm for predicting pathological complete response (pCR) in the early TNBC population treated with neoadjuvant chemotherapy.,Identify women with chemotherapy sensitive and chemotherapy resistant breast cancers.
Summary
Background: Despite improvements in the treatment of Triple Negative Breast Cancer (TNBC),
 the cancer returns in half of the women and shockingly 40% are dead within 5 years of their
 initial cancer diagnosis. There is an urgent need to identify reliable biomarkers of response
 for chemotherapy and immunotherapy.
 
 Study Aims: To update Concr's existing predictive algorithms specifically for use in women
 newly diagnosed with TNBC.
 
 The plan is develop technology which will predict which drug the cancer will respond best to,
 treatment A vs. treatment B AND how the individual's prognosis could change if treatment A is
 chosen overtreatment B.
 
 Study Design: The VISION study is a clinical study looking back in time (retrospective
 study), specifically focusing on women who were previously diagnosed with early Triple
 Negative breast cancer and received chemotherapy followed by curative breast surgery. The
 plan is to collect historical clinical data and previously collected cancer biopsy samples
 from up to 200 women in order to update Concr's existing treatment prediction algorithms.
 Hence there are no extra research biopsies needed in order to participate in the Study.
 
 Study Sites: UK and Australia
 
 Study Funding: This study is funded by the a Techbio company called Concr with support from
 Innovate UK (UK Government funding).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06409221
Non-Device Trial